Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ: PTCT )

51.82 +2.15 (+4.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
What 5 Analyst Ratings Have To Say About PTC Therapeutics
Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for PTC Therapeutics
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter: 
Via Benzinga
Analyst Ratings for PTC Therapeutics
Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings: 
Via Benzinga
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022
Upgrades 
Via Benzinga
Analyst Ratings for PTC Therapeutics
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter: 
Via Benzinga
PTC Therapeutics: Q2 Earnings Insights
PTC Therapeutics (NASDAQ:PTCT) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
Newman Ferrara LLP Announces Corporate Governance Investigations of PTC Therapeutics (PTCT)
From Newman Ferrara LLP
Via Business Wire
Raymond James Says PTC Therapeutics' CHMP Backing Is 'Under Exceptional Circumstances' What's Next
Via Benzinga
Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder
Via Benzinga
Earnings Scheduled For February 22, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
Upgrades 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
  
Via Benzinga
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
PTC Stock Has Gained 27% This Week Alone, And It's Still Sprinting
Shares of PTC stock continued a seven-day run Thursday on promising test results for its Duchenne muscular dystrophy treatment. 
Via Investor's Business Daily
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 36 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
PTC Therapeutics's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $148.74 million. Despite a 11.54% increase in earnings, the company posted a loss of $126.73... 
Via Benzinga
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter. 
Via Benzinga
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Recap: PTC Therapeutics Q4 Earnings
PTC Therapeutics (NASDAQ:PTCT) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
PTC Therapeutics Inc (PTCT) Q3 2021 Earnings Call Transcript
PTCT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.